Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 7;83(18):1799-1817.
doi: 10.1016/j.jacc.2023.09.840.

Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5

Affiliations
Free article
Review

Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5

Rodrigo Estévez-Loureiro et al. J Am Coll Cardiol. .
Free article

Abstract

Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is <1%, mitral regurgitation after acute myocardial infarction frequently causes hemodynamic instability, pulmonary edema, and cardiogenic shock. Medical management has the worst prognosis, and mortality has not changed in decades. Surgery represents the gold standard, but it is associated with high rates of morbidity and mortality. Recently, transcatheter interventions have opened a new door for management that may improve survival. Mechanical circulatory support restores vital organ perfusion and offers the opportunity for a steadier surgical repair. This review focuses on the diagnosis and the interventional management, both surgical and transcatheter, with a glance on future perspectives to enhance patient management and eventually decrease mortality.

Keywords: mechanical complication; mitral regurgitation; myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Estévez-Loureiro is a consultant for Abbott Vascular, Edwards Lifesciences, Boston Scientific, and Venus Medtech. Dr Taramasso has served as a consultant for Abbott Vascular, Boston Scientific, 4TECH, and CoreMedic; and has received speaker honoraria from Edwards Lifesciences. Dr Lorusso is a consultant for Medtronic, Abiomed, and ChinaBridge Medical; is a member of the Medical Advisory Board of Eurosets and Xenios; and has received a grant for research activity from Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

MeSH terms

LinkOut - more resources